Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study.

Wu JY, Lee KW, Huang SC, Chang HY, Lin YM

Diabetes research and clinical practice19 Apr 2026Cited by 1 (Europe PMC)

PMID42009260DOI10.1016/j.diabres.2026.113273PepBankPUB-42009260

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanObservational studyEfficacy outcome
In adults with early cardiovascular-kidney-metabolic syndrome, progression to stage 3-4 occurred in 2.2% with tirzepatide versus 3.3% with other GLP-1 RAs (HR 0.88).
In plain wordsIn adults with early cardiovascular-kidney-metabolic disease, fewer people on tirzepatide than on other GLP-1 drugs progressed to later stages.
Peptide
Tirzepatide
Outcome
DecreaseProgression to CKM stage 3-4
Study
n = 448,591
Comparator
Other GLP-1 receptor agonists
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
progression to CKM stage 3-4
2.2%
tirzepatide
progression to CKM stage 3-4
3.3%
GLP-1 RA
HR
0.88 ratio
tirzepatide versus GLP-1 RA
Source sentences
Summary
progression to CKM stage 3-4 occurred in 2.2% of patients receiving tirzepatide and 3.3% receiving GLP-1 RAs (HR 0.88, 95% CI 0.86-0.91; P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with CKM stage 1 or 2 who newly initiated tirzepatide or another GLP-1 RA were identified.
Summary · context
A new-user design with 1:1 propensity score matching was applied to balance demographic characteristics, comorbidities, medications, and laboratory parameters.
Report a problemFND-4200926001
02HumanObservational studyEfficacy outcome
In adults with early cardiovascular-kidney-metabolic syndrome, tirzepatide was associated with lower MACE risk than other GLP-1 RAs (HR 0.85).
In plain wordsIn adults with early cardiovascular-kidney-metabolic disease, tirzepatide was linked to fewer major cardiovascular events than other GLP-1 drugs.
Peptide
Tirzepatide
Outcome
DecreaseMACE
Study
n = 448,591
Comparator
Other GLP-1 receptor agonists
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
HR
0.85 ratio
MACE
Source sentences
Summary
lower risks of MACE (HR 0.85, 95% CI 0.80-0.89)
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with CKM stage 1 or 2 who newly initiated tirzepatide or another GLP-1 RA were identified.
Summary · context
A new-user design with 1:1 propensity score matching was applied to balance demographic characteristics, comorbidities, medications, and laboratory parameters.
Report a problemFND-4200926002
03HumanObservational studyEfficacy outcome
In adults with early cardiovascular-kidney-metabolic syndrome, tirzepatide was associated with lower risk of coronary artery disease than other GLP-1 RAs.
In plain wordsIn adults with early cardiovascular-kidney-metabolic disease, tirzepatide was linked to less coronary artery disease than other GLP-1 drugs.
Peptide
Tirzepatide
Outcome
DecreaseCoronary artery disease
Study
n = 448,591
Comparator
Other GLP-1 receptor agonists
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide was also associated with lower risks of MACE (HR 0.85, 95% CI 0.80-0.89), coronary artery disease, peripheral artery disease, ischemic stroke, heart failure, very high-risk chronic kidney disease, and all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with CKM stage 1 or 2 who newly initiated tirzepatide or another GLP-1 RA were identified.
Summary · context
A new-user design with 1:1 propensity score matching was applied to balance demographic characteristics, comorbidities, medications, and laboratory parameters.
Report a problemFND-4200926003
04HumanObservational studyEfficacy outcome
In adults with early cardiovascular-kidney-metabolic syndrome, tirzepatide was associated with lower risk of peripheral artery disease than other GLP-1 RAs.
In plain wordsIn adults with early cardiovascular-kidney-metabolic disease, tirzepatide was linked to less peripheral artery disease than other GLP-1 drugs.
Peptide
Tirzepatide
Outcome
DecreasePeripheral artery disease
Study
n = 448,591
Comparator
Other GLP-1 receptor agonists
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide was also associated with lower risks of MACE (HR 0.85, 95% CI 0.80-0.89), coronary artery disease, peripheral artery disease, ischemic stroke, heart failure, very high-risk chronic kidney disease, and all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with CKM stage 1 or 2 who newly initiated tirzepatide or another GLP-1 RA were identified.
Summary · context
A new-user design with 1:1 propensity score matching was applied to balance demographic characteristics, comorbidities, medications, and laboratory parameters.
Report a problemFND-4200926004
05HumanObservational studyEfficacy outcome
In adults with early cardiovascular-kidney-metabolic syndrome, tirzepatide was associated with lower risk of ischemic stroke than other GLP-1 RAs.
In plain wordsIn adults with early cardiovascular-kidney-metabolic disease, tirzepatide was linked to fewer ischemic strokes than other GLP-1 drugs.
Peptide
Tirzepatide
Outcome
DecreaseIschemic stroke
Study
n = 448,591
Comparator
Other GLP-1 receptor agonists
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide was also associated with lower risks of MACE (HR 0.85, 95% CI 0.80-0.89), coronary artery disease, peripheral artery disease, ischemic stroke, heart failure, very high-risk chronic kidney disease, and all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with CKM stage 1 or 2 who newly initiated tirzepatide or another GLP-1 RA were identified.
Summary · context
A new-user design with 1:1 propensity score matching was applied to balance demographic characteristics, comorbidities, medications, and laboratory parameters.
Report a problemFND-4200926005
06HumanObservational studyEfficacy outcome
In adults with early cardiovascular-kidney-metabolic syndrome, tirzepatide was associated with lower risk of heart failure than other GLP-1 RAs.
In plain wordsIn adults with early cardiovascular-kidney-metabolic disease, tirzepatide was linked to less heart failure than other GLP-1 drugs.
Peptide
Tirzepatide
Outcome
DecreaseHeart failure
Study
n = 448,591
Comparator
Other GLP-1 receptor agonists
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide was also associated with lower risks of MACE (HR 0.85, 95% CI 0.80-0.89), coronary artery disease, peripheral artery disease, ischemic stroke, heart failure, very high-risk chronic kidney disease, and all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with CKM stage 1 or 2 who newly initiated tirzepatide or another GLP-1 RA were identified.
Summary · context
A new-user design with 1:1 propensity score matching was applied to balance demographic characteristics, comorbidities, medications, and laboratory parameters.
Report a problemFND-4200926006
07HumanObservational studyEfficacy outcome
In adults with early cardiovascular-kidney-metabolic syndrome, tirzepatide was associated with lower risk of very high-risk chronic kidney disease than other GLP-1 RAs.
In plain wordsIn adults with early cardiovascular-kidney-metabolic disease, tirzepatide was linked to less very high-risk kidney disease than other GLP-1 drugs.
Peptide
Tirzepatide
Outcome
DecreaseVery high-risk chronic kidney disease
Study
n = 448,591
Comparator
Other GLP-1 receptor agonists
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide was also associated with lower risks of MACE (HR 0.85, 95% CI 0.80-0.89), coronary artery disease, peripheral artery disease, ischemic stroke, heart failure, very high-risk chronic kidney disease, and all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with CKM stage 1 or 2 who newly initiated tirzepatide or another GLP-1 RA were identified.
Summary · context
A new-user design with 1:1 propensity score matching was applied to balance demographic characteristics, comorbidities, medications, and laboratory parameters.
Report a problemFND-4200926007
08HumanObservational studyEfficacy outcome
In adults with early cardiovascular-kidney-metabolic syndrome, tirzepatide was associated with lower all-cause mortality than other GLP-1 RAs.
In plain wordsIn adults with early cardiovascular-kidney-metabolic disease, tirzepatide was linked to fewer deaths than other GLP-1 drugs.
Peptide
Tirzepatide
Outcome
DecreaseAll-cause mortality
Study
n = 448,591
Comparator
Other GLP-1 receptor agonists
Analysis
Secondary
Outcome group
Mortality · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide was also associated with lower risks of MACE (HR 0.85, 95% CI 0.80-0.89), coronary artery disease, peripheral artery disease, ischemic stroke, heart failure, very high-risk chronic kidney disease, and all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with CKM stage 1 or 2 who newly initiated tirzepatide or another GLP-1 RA were identified.
Summary · context
A new-user design with 1:1 propensity score matching was applied to balance demographic characteristics, comorbidities, medications, and laboratory parameters.
Report a problemFND-4200926008
09HumanObservational studyEfficacy outcome
In adults with early cardiovascular-kidney-metabolic syndrome, no significant difference in atrial fibrillation was observed between tirzepatide and other GLP-1 RAs.
In plain wordsIn adults with early cardiovascular-kidney-metabolic disease, atrial fibrillation did not differ between tirzepatide and other GLP-1 drugs.
Peptide
Tirzepatide
Outcome
No significant changeAtrial fibrillation
Study
n = 448,591
Comparator
Other GLP-1 receptor agonists
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
No significant difference was observed for atrial fibrillation.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with CKM stage 1 or 2 who newly initiated tirzepatide or another GLP-1 RA were identified.
Summary · context
A new-user design with 1:1 propensity score matching was applied to balance demographic characteristics, comorbidities, medications, and laboratory parameters.
Report a problemFND-4200926009
10HumanObservational studyEfficacy outcome
In adults with early cardiovascular-kidney-metabolic syndrome, associations were consistent across prespecified subgroups including age, sex, baseline CKM stage, obesity status and statin use.
In plain wordsIn adults with early cardiovascular-kidney-metabolic disease, the links for tirzepatide were similar across age, sex, disease stage, obesity and statin use groups.
Peptide
Tirzepatide
Outcome
Not applicableConsistency across prespecified subgroups
Study
n = 448,591
Comparator
Other GLP-1 receptor agonists
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Associations were consistent across prespecified subgroups, including age, sex, baseline CKM stage, obesity status, and statin use.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with CKM stage 1 or 2 who newly initiated tirzepatide or another GLP-1 RA were identified.
Summary · context
A new-user design with 1:1 propensity score matching was applied to balance demographic characteristics, comorbidities, medications, and laboratory parameters.
Report a problemFND-4200926010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.